Next Science Limited (NXS.AX)
- Previous Close
0.0800 - Open
0.0810 - Bid 0.0810 x --
- Ask 0.0850 x --
- Day's Range
0.0810 - 0.0820 - 52 Week Range
0.0800 - 0.3050 - Volume
143,243 - Avg. Volume
177,280 - Market Cap (intraday)
23.957M - Beta (5Y Monthly) 1.31
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0600 - Earnings Date Feb 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.27
Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.
www.nextscience.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: NXS.AX
View MorePerformance Overview: NXS.AX
Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NXS.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NXS.AX
View MoreValuation Measures
Market Cap
23.96M
Enterprise Value
25.23M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.68
Price/Book (mrq)
4.49
Enterprise Value/Revenue
0.71
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-46.40%
Return on Assets (ttm)
-47.12%
Return on Equity (ttm)
-130.18%
Revenue (ttm)
22.82M
Net Income Avi to Common (ttm)
-10.59M
Diluted EPS (ttm)
-0.0600
Balance Sheet and Cash Flow
Total Cash (mrq)
1.67M
Total Debt/Equity (mrq)
72.42%
Levered Free Cash Flow (ttm)
-5.09M